P/E ratio for Incyte (INCY)
P/E ratio as of May 2024 (TTM): 30.0
According to Incyte's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 30.0263. At the end of 2022 the company had a P/E ratio of 52.2.
P/E ratio history for Incyte from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 52.2 | 204.83% |
| 2021 | 17.1 | -127.34% |
| 2020 | -62.6 | -249.06% |
| 2019 | 42.0 | -65.67% |
| 2018 | 122 | -301.43% |
| 2017 | -60.7 | -133.91% |
| 2016 | 179 | -96.7% |
| 2015 | > 1000 | -2325.07% |
| 2014 | -244 | 159.92% |
| 2013 | -93.8 | 103.21% |
| 2012 | -46.1 | 354.93% |
| 2011 | -10.1 | -84.08% |
| 2010 | -63.7 | 1340.24% |
| 2009 | -4.42 | 131.03% |
| 2008 | -1.91 | -80.38% |
| 2007 | -9.76 | 48.7% |
| 2006 | -6.56 | 51.14% |
| 2005 | -4.34 | -3.96% |
| 2004 | -4.52 | 54.64% |
| 2003 | -2.92 | 30.13% |
| 2002 | -2.25 | -67.99% |
| 2001 | -7.02 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 27.6 | -8.08% | 🇨🇭 Switzerland |
 Pfizer PFE | 15.5 | -48.40% | 🇺🇸 USA |
 Eli Lilly LLY | 145 | 382.77% | 🇺🇸 USA |
 Amgen AMGN | 22.5 | -24.91% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 54.6 | 81.94% | 🇺🇸 USA |
 Geron GERN | -11.5 | -138.20% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -15.7 | -152.20% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -17.9 | -159.47% | 🇺🇸 USA |
 Ardelyx ARDX | -65.4 | -317.86% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.